| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.057 | 0.1 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | -0.049 | 0.1 |
| mRNA | BMS-509744 | GDSC1000 | pan-cancer | AAC | -0.08 | 0.1 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | 0.059 | 0.1 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | 0.052 | 0.1 |
| mRNA | AZD1480 | CTRPv2 | pan-cancer | AAC | -0.083 | 0.1 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | -0.06 | 0.1 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | 0.06 | 0.1 |